GlobeNewswire

Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

Share

Allschwil, Switzerland – September 2, 2020

Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the presentation of additional data on the effect of treatment with ponesimod versus teriflunomide on disability measures in patients with relapsing multiple sclerosis as part of MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

For further details on the 13 company-sponsored data presentations from its multiple sclerosis research program please read the full announcement from Janssen available at www.janssen.com.

Idorsia and Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a revenue-sharing agreement in respect to ponesimod. Under the terms of the revenue-sharing agreement, Idorsia is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion Pharmaceuticals Ltd.

Notes to the editor

About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease1.12.2020 22:01:00 CETPress release

Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737. The drug candidate or placebo will be administered for 52 weeks in up to 60 ADPKD patients with rapidly progressing disease. Patients will be randomized in a 2:1 ratio of treatment to placebo. Primary objectives of the trial are to assess the growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability. Secondary measures include renal function, pharmacokinetics, and pharmacodynamics. Recruitment for the MANGROVE trial is planned in 7 countries in Europe. GLPG2737 is a CFTR1 inhibitor which was shown to be well tolerated by patients in previous clinical trials. It is hypothesi

REC Silicon – Cancellation of subsequent offering1.12.2020 20:13:46 CETPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Lysaker, 1 December 2020 Reference is made to the stock exchange announcements by REC Silicon ASA (the "Company") on 14 October 2020 and 15 October 2020 regarding the successful completion of a private placement raising gross proceeds of approximately NOK 1,000 million (the "Private Placement") and a potential subsequent offering (the "Subsequent Offering") of up to 18,518,518 new shares directed towards shareholders of the Company as of 14 October 2020 who were not allocated shares in the Private Placement. The Company has decided not to initiate the Subsequent Offering. The background for the cancellation is that the Company's shares have over time traded on the Oslo Stock Exchange, with significant trading volume, at prices below the subscription pric

Bombardier and Alstom Confirm Receipt of All Necessary Regulatory Approvals to Complete Bombardier Transportation Sale to Alstom1.12.2020 18:24:09 CETPress release

MONTRÉAL, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) and Alstom announced today that all necessary regulatory approvals required to complete the sale of Bombardier Transportation to Alstom have been received. Bombardier and Alstom now expect the transaction to close on January 29, 2021. About Bombardier With over 52,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are availab

FDA approves Xolair® (omalizumab) for adults with nasal polyps1.12.2020 18:07:00 CETPress release

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammationXolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key d

Tecan raises forecast for the full year of 2020 based on continued extraordinary demand for COVID-19 related products1.12.2020 18:02:00 CETPress release

Sales growth now expected to be in the low to mid-teens percentage range in local currenciesReported EBITDA margin now forecasted above 20.5% of sales Männedorf, Switzerland, 1 December, 2020 – Based on the strong business performance year to date, as well as on the high order backlog and the continued elevated demand for COVID-19 related products, the Tecan Group (SIX Swiss Exchange: TECN) once again raised its outlook for full-year sales and reported EBITDA margin. These updated projections continue to be based on the assumptions that also for the remainder of the year supply chains and freight logistics remain undisrupted and all production sites stay fully operational. Based on continued strong demand for a number of product lines to help in the global fight against the coronavirus pandemic, Tecan now forecasts sales growth for full-year 2020 to be in the low to mid-teens percentage range in local currencies (latest guidance from August 12, 2020: “high single-digit percentage range

Touax: Successful asset refinancing - Containers Business1.12.2020 17:45:00 CETPress release

PRESS RELEASE Paris, December 1, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Successful asset refinancing - Containers Business Touax announces today that it has successfully refinanced asset-backed facilities of its Container division for a total of US$ 75 million, versus US$ 60 million previously, combining a Term Loan of US$ 37 million and a Revolving Credit Facility (RCF) of US$ 38 million with a two-year maturity. The documentation provides for an accordion option, allowing the line to be scaled up to US$ 85 million, to support growth. This operation allows the refinancing of the existing portfolio of assets as well as the financing of future investments. Touax Container Asset Finance Ltd will thus continue to invest for its development, particularly in the purchase of equipment for leasing purpose. Financing is granted by ABN AMRO Bank N.V., ING Belgium SA / NV and NIBC Bank N.V. Touax was advised by Stephenson Harwood (Legal Counsel). “We ar